Vimizim and Joint pain - a phase IV clinical study of FDA data

Summary:

Joint pain is reported as a side effect among people who take Vimizim (elosulfase alfa), especially for people who are female, 10-19 old, have been taking the drug for 5 - 10 years also take Heparin, and have Pain.

The phase IV clinical study analyzes which people have Joint pain when taking Vimizim. It is created by eHealthMe based on reports of 4,772 people who have side effects when taking Vimizim from the FDA, and is updated regularly.

What is Vimizim?

Vimizim has active ingredients of elosulfase alfa. eHealthMe is studying from 4,772 Vimizim users. Check the latest studies of Vimizim.

What is Joint pain?

Joint pain is found to be associated with 3,328 drugs and 5,208 conditions by eHealthMe. Check the latest studies of Joint pain.

On Jul, 23, 2026

4,772 people reported to have side effects when taking Vimizim.
Among them, 136 people (2.85%) have Joint pain.

Among these 136 people:

* Approximation only. Some reports may have incomplete information.

Do you take Vimizim and have Joint pain?

- Check whether Joint pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimizim:

Vimizim (4,772 reports)

Joint pain treatments and more:

Joint pain (542,934 reports)

How severe was Joint pain and when was it recovered:

Joint pain in Vimizim

Expand to all the drugs that have ingredients of elosulfase alfa:

Joint pain and drugs with ingredients of elosulfase alfa (136 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vimizim:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint pain:

Joint pain (3,328 drugs)

Browse all the conditions that are associated with Joint pain:

Joint pain (5,208 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elosulfase alfa (the active ingredients of Vimizim) and Vimizim (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.